Hospital
Sun City Hospital INC
Sun City Hospital INC was paid $1.90M by Medicaid between Jan 2018 and Nov 2024, across 67 billing codes. Its largest line is 99283, emergency room visit (moderate) — 44% of everything it billed.
33Billing provider infoSUN CITY HOSPITAL INC
SUN CITY CENTER, FL 33573
SUN CITY CENTER, FL 33573
33aNPI1164476867assigned 05/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.90M
24GClaims80,923
24DCodes billed67
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#121 of 163
Median peer was paid$4.77M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,303 | $47K | |
| 2019 | 18,466 | $187K | |
| 2020 | 13,257 | $138K | |
| 2021 | 16,201 | $410K | |
| 2022 | 15,421 | $586K | |
| 2023 | 8,776 | $343K | |
| 2024incomplete | 3,499 | $183K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 44% | 10,498 | 9,508 | $840K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 7,068 | 5,915 | $363K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.3% | 803 | 717 | $138K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.2% | 1,289 | 1,009 | $99K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 1,188 | 1,100 | $80K |
| 80053 | Comprehensive metabolic panel | 3.8% | 6,223 | 5,056 | $72K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 1,228 | 1,010 | $68K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 172 | 156 | $39K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 411 | 382 | $37K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 196 | 177 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 302 | 285 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,696 | 2,222 | $13K |
55 more codes
| 87070 | <1% | 804 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,444 | $10K |
| 81001 | <1% | 3,241 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 582 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,976 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 337 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,340 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,164 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,006 | $5K |
| 84484 | <1% | 2,603 | $5K | |
| 81025 | <1% | 1,948 | $4K | |
| 85027 | <1% | 7,196 | $4K | |
| 81003 | <1% | 562 | $3K | |
| 87040 | <1% | 321 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,615 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 506 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,495 | $2K |
| 87420 | <1% | 119 | $2K | |
| 85610 | <1% | 1,719 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,634 | $1K |
| 84702 | <1% | 98 | $1K | |
| A9270 | Non-covered item or service | <1% | 858 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,583 | $1K |
| G0378 | Hospital observation service, per hour | <1% | 284 | $881.79 |
| 85730 | <1% | 709 | $878.82 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 16 | $874.56 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 84 | $834.22 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 71 | $700.57 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,975 | $681.46 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 398 | $658.92 |
| 83735 | <1% | 1,495 | $618.35 | |
| 85379 | <1% | 76 | $304.59 | |
| 83690 | <1% | 1,712 | $197.01 | |
| 87077 | <1% | 31 | $174.63 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 202 | $150.54 |
| 84703 | <1% | 124 | $112.25 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 46 | $104.09 |
| 93975 | <1% | 12 | $88.61 | |
| 84145 | <1% | 18 | $48.84 | |
| 96376 | <1% | 38 | $29.02 | |
| 86900 | <1% | 28 | $12.50 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 575 | $5.31 |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 41 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 26 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 28 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 221 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 116 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 18 | $0.00 |
| 83880 | 0% | 181 | $0.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 21 | $0.00 |
| 83605 | 0% | 82 | $0.00 | |
| 86901 | 0% | 14 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 26 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 13 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH-FRAYER, KAMARIA (CFO)